NEOASIS at ESMO 2026: Neoadjuvant Botensilimab Plus Balstilimab in dMMR Colorectal Cancer

Agenus presented Phase II NEOASIS study results at ESMO 2026, showing 83% pathological response rate in dMMR colorectal cancer patients treated with neoadjuvant botensilimab plus balstilimab. 72% achieved complete response. Safety profile included Grade 1-2 immune-related adverse events in 72% of patients, with one Grade 3 colitis case. The study met its primary endpoint, supporting further evaluation.

Original reporting
Published Oct 27, 2026, 8:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 9:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
NEOASIS at ESMO 2026: Neoadjuvant Botensilimab Plus Balstilimab in dMMR Colorectal Cancer — source image
Decision brief

The 30-second read

$AGENBullishMed
01

Why it matters

The high major pathological response rate (83%) and 72% complete responses suggest a promising neoadjuvant regimen, likely prompting analyst upgrades and short‑term buying interest.

02

Market read

First public disclosure of Phase II efficacy data for a novel neoadjuvant immunotherapy, a material catalyst for the stock.

03

What to watch

Potential safety concerns with Grade 3 colitis and ileus could temper enthusiasm

Relevance 8/10Novelty 8/10Timing: post-ESMO release

Background

Agenus (NASDAQ: AGEN) disclosed early clinical data at the European Society for Medical Oncology (ESMO) 2026 Congress.

Company-level read

Ticker impact

$AGENBullishHigh confidence
Context

Agenus presented Phase II NEOASIS data showing 83% major pathological response in dMMR colorectal cancer.

Expected impact

likely upward pressure as investors price in strong efficacy signals

Evidence & confidence

Phase II data with high response rates is material for a biotech; market typically reacts positively to such early‑stage success.

Market effects

strengthens outlook for immunotherapy in dMMR colorectal cancer and may benefit peers in checkpoint inhibitor space

European biotech investors may see increased interest following ESMO presentation

adds to global pipeline momentum for checkpoint blockade therapies

Counterpoint

Data is from a small Phase II cohort; efficacy may not translate to larger trials, risk of overvaluation

Key entities

  • Agenus

    Biopharma developing checkpoint inhibitor antibodies botensilimab and balstilimab.

  • Emma van den Berg

    Presenter of the NEOASIS results at ESMO.

Related articles

$AGENMedAI 8/10

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

$AGENMedAI 8/10

Agenus advances Phase 3 colon cancer trial, posts Q3 profit

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.